TORONTO, Nov. 2 /CNW/ - Lorus Therapeutics Inc. (‘Lorus’), a biopharmaceutical company specializing in the development and commercialization of pharmaceutical products and technologies for the management of cancer, today announced the reduction of staff by approximately 35%.
